A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT ID: NCT02247479

Last Updated: 2019-06-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

906 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-18

Study Completion Date

2018-01-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Geographic Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lampalizumab Once in Every 4 Weeks (Q4W)

Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.

Group Type EXPERIMENTAL

Lampalizumab

Intervention Type DRUG

Participants will receive 10 mg dose of lampalizumab administered intravitreally.

Lampalizumab Once in Every 6 Weeks (Q6W)

Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.

Group Type EXPERIMENTAL

Lampalizumab

Intervention Type DRUG

Participants will receive 10 mg dose of lampalizumab administered intravitreally.

Sham Comparator

Participants will receive sham comparator Q4W or Q6W for 96 weeks.

Group Type SHAM_COMPARATOR

Sham

Intervention Type OTHER

A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lampalizumab

Participants will receive 10 mg dose of lampalizumab administered intravitreally.

Intervention Type DRUG

Sham

A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RO5490249

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Well demarcated area(s) of Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with no evidence of prior or active choroidal neovascularization (CNV) in both eyes

Exclusion Criteria

* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
* Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and proliferative diabetic retinopathy
* GA in either eye due to causes other than AMD
* Previous treatment with eculizumab, lampalizumab and/or fenretinide
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uni of Alabama At Birmingham Clinical Research Unit

Birmingham, Alabama, United States

Site Status

Retinal Research Institute, LLC

Phoenix, Arizona, United States

Site Status

Retina Centers P.C.

Tucson, Arizona, United States

Site Status

California Retina Consultants

Bakersfield, California, United States

Site Status

Retina-Vitreous Associates Medical Group

Beverly Hills, California, United States

Site Status

The Gavin Herbert Eye Institute - UC, Irvine

Irvine, California, United States

Site Status

Jules Stein Eye Institute/ UCLA

Los Angeles, California, United States

Site Status

East Bay Retina Consultants

Oakland, California, United States

Site Status

Southern CA Desert Retina Cons

Palm Desert, California, United States

Site Status

W Coast Retina Med Group Inc

San Francisco, California, United States

Site Status

UCSF; Ophthalmology

San Francisco, California, United States

Site Status

Orange County Retina Med Group

Santa Ana, California, United States

Site Status

California Retina Consultants

Santa Barbara, California, United States

Site Status

Florida Eye Microsurgical Inst

Boynton Beach, Florida, United States

Site Status

National Ophthalmic Research Institute

Fort Myers, Florida, United States

Site Status

Florida Eye Associates

Melbourne, Florida, United States

Site Status

Retina Care Specialists

Palm Beach Gardens, Florida, United States

Site Status

Bascom Palmer Eye Institute

Palm Beach Gardens, Florida, United States

Site Status

Retina Specialty Institute

Pensacola, Florida, United States

Site Status

Fort Lauderdale Eye Institute

Plantation, Florida, United States

Site Status

Retina Vitreous Assoc of FL

St. Petersburg, Florida, United States

Site Status

Southern Vitreoretinal Assoc

Tallahassee, Florida, United States

Site Status

Retina Associates of Florida, LLC

Tampa, Florida, United States

Site Status

Southeast Retina Center

Augusta, Georgia, United States

Site Status

Georgia Retina PC

Marietta, Georgia, United States

Site Status

Retina Consultants of Hawaii

‘Aiea, Hawaii, United States

Site Status

Northwestern Medical Group/Northwestern University

Chicago, Illinois, United States

Site Status

University Retina and Macula Associates, PC

Oak Forest, Illinois, United States

Site Status

Midwest Eye Institute Northside

Indianapolis, Indiana, United States

Site Status

Wolfe Eye Clinic

West Des Moines, Iowa, United States

Site Status

Retina Associates

Shawnee Mission, Kansas, United States

Site Status

Lahey Clinic Med Ctr

Lexington, Kentucky, United States

Site Status

Retina Associates of Kentucky

Lexington, Kentucky, United States

Site Status

Maine Eye Center

Portland, Maine, United States

Site Status

Retina Specialists

Towson, Maryland, United States

Site Status

Tufts Medical Center Research

Boston, Massachusetts, United States

Site Status

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Site Status

Vitreo-Retinal Associates, PC

Worcester, Massachusetts, United States

Site Status

Vitreo-Retinal Associates

Grand Rapids, Michigan, United States

Site Status

Specialty Eye Institute

Jackson, Michigan, United States

Site Status

Assoc Retinal Consultants PC

Royal Oak, Michigan, United States

Site Status

Retina Consultants of Michigan

Southfield, Michigan, United States

Site Status

Eye Surgical Associates

Lincoln, Nebraska, United States

Site Status

Retina Consultants of Nevada

Las Vegas, Nevada, United States

Site Status

Retina Center of New Jersey

Bloomfield, New Jersey, United States

Site Status

New Jersey Retina Research Foundation

Edison, New Jersey, United States

Site Status

Delaware Valley Retina Assoc

Lawrenceville, New Jersey, United States

Site Status

Long Is. Vitreoretinal Consult

Hauppauge, New York, United States

Site Status

Opthalmic Consultants of LI

Lynbrook, New York, United States

Site Status

New York Eye & Ear Infirmary

New York, New York, United States

Site Status

Retina Consultants of Western New York

Orchard Park, New York, United States

Site Status

Retina Vit Surgeons/Central NY

Syracuse, New York, United States

Site Status

Western Carolina Retinal Associate PA

Asheville, North Carolina, United States

Site Status

Wake Forest Baptist Health Eye Centre

Winston-Salem, North Carolina, United States

Site Status

Retina Assoc of Cleveland Inc

Beachwood, Ohio, United States

Site Status

Cleveland Clinic Foundation; Cole Eye Institute

Cleveland, Ohio, United States

Site Status

Retina Vitreous Consultants

Monroeville, Pennsylvania, United States

Site Status

Associates in Ophthalmology

West Mifflin, Pennsylvania, United States

Site Status

Charleston Neuroscience Inst

Ladson, South Carolina, United States

Site Status

Tennessee Retina PC.

Nashville, Tennessee, United States

Site Status

Vanderbilt

Nashville, Tennessee, United States

Site Status

Retina Res Institute of Texas

Abilene, Texas, United States

Site Status

Texas Retina Associates

Arlington, Texas, United States

Site Status

Austin Retina Associates

Austin, Texas, United States

Site Status

Retina Research Center

Austin, Texas, United States

Site Status

UT Southwestern MC at Dallas

Dallas, Texas, United States

Site Status

Valley Retina Institute P.A.

McAllen, Texas, United States

Site Status

Strategic Clinical Research Group, LLC

Willow Park, Texas, United States

Site Status

Retina Associates of Utah

Salt Lake City, Utah, United States

Site Status

Eye Surgeons of Richmond Inc. dba Virginia Eye Institute

Richmond, Virginia, United States

Site Status

Retina Institute of Virginia

Richmond, Virginia, United States

Site Status

Virginia Retina Center

Warrenton, Virginia, United States

Site Status

Retina Center Northwest

Silverdale, Washington, United States

Site Status

Spokane Eye Clinical Research

Spokane, Washington, United States

Site Status

West Virginia University Eye Institute

Morgantown, West Virginia, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

Organizacion Medica de Investigacion

Buenos Aires, , Argentina

Site Status

Fundacion Zambrano

CABA, , Argentina

Site Status

Oftar

Mendoza, , Argentina

Site Status

Microcirugía Ocular S.A

Rosario, , Argentina

Site Status

Grupo Laser Vision

Rosario, , Argentina

Site Status

Eyeclinic Albury Wodonga

Albury, New South Wales, Australia

Site Status

Marsden Eye Research Centre

Parramatta, New South Wales, Australia

Site Status

Save Sight Institute

Sydney, New South Wales, Australia

Site Status

Sydney West Retina

Westmead, New South Wales, Australia

Site Status

Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Augenheilkunde

Linz, , Austria

Site Status

CHU Brugmann (Victor Horta)

Brussels, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

UZ Leuven Sint Rafael

Leuven, , Belgium

Site Status

CHU Sart-Tilman

Liège, , Belgium

Site Status

Calgary Retina Consultants

Calgary, Alberta, Canada

Site Status

University of British Columbia

Vancouver, British Columbia, Canada

Site Status

QEII - HSC Department of Ophthalmology

Halifax, Nova Scotia, Canada

Site Status

University of Ottawa Eye Institute

Ottawa, Ontario, Canada

Site Status

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status

St. Michael'S Hospital

Toronto, Ontario, Canada

Site Status

University Health Network Toronto Western Hospital

Toronto, Ontario, Canada

Site Status

Institut De L'Oeil Des Laurentides

Boisbriand, Quebec, Canada

Site Status

Sjællands Universitetshospital, Roskilde; Øjenafdelingen

Roskilde, , Denmark

Site Status

Chi De Creteil; Ophtalmologie

Créteil, , France

Site Status

Centre Odeon; Exploration Ophtalmologique

Paris, , France

Site Status

Hopital Lariboisiere; Ophtalmologie

Paris, , France

Site Status

Centre Ophtalmologique; Imagerie et laser

Paris, , France

Site Status

Ch Pitie Salpetriere; Ophtalmologie

Paris, , France

Site Status

CHU Poitiers - CHR La Miletrie; Ophtalmologie

Poitiers, , France

Site Status

Universitäts-Augenklinik Bonn

Bonn, , Germany

Site Status

Universitätsklinikum Köln; Augenklinik

Cologne, , Germany

Site Status

Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Augenheilkunde

Göttingen, , Germany

Site Status

Medizinische Hochschule Hannover, Klinik für Augenheilkunde

Hanover, , Germany

Site Status

Universitätskliniikum Schleswig-Holstein, Campus Lübeck, Klinik für Augenheilkunde

Lübeck, , Germany

Site Status

Augenabteilung am St. Franziskus-Hospital

Münster, , Germany

Site Status

Universitätsklinikum Münster; Augenheilkunde

Münster, , Germany

Site Status

Budapest Retina Associates Kft.

Budapest, , Hungary

Site Status

Debreceni Egyetem Klinikai Kozpont; Szemeszeti Klinika

Debrecem, , Hungary

Site Status

Ganglion Medial Center

Pécs, , Hungary

Site Status

Fondazione Ptv Policlinico Tor Vergata Di Roma;U.O.S.D. Patologie Renitiche

Rome, Lazio, Italy

Site Status

Fondazione G.B. Bietti Per Lo Studio E La Ricerca in Oftalmologia-Presidio Ospedaliero Britannico

Rome, Lazio, Italy

Site Status

Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico-Clinica Regina Elena;U.O.C Oculistica

Milan, Lombardy, Italy

Site Status

Azienda Ospedaliero Universitaria Di Sassari;U.O. Oculistica

Sassari, Sardinia, Italy

Site Status

Macula Retina Consultores

Mexico City, , Mexico

Site Status

Hospital de la Ceguera APEC

Mexico City, , Mexico

Site Status

Academisch Medisch Centrum Universiteit Amsterdam

Amsterdam, , Netherlands

Site Status

Leids Universitair Medisch Centrum

Leiden, , Netherlands

Site Status

Radboud University Nijmegen Medical Centre; Ophthalmology

Nijmegen, , Netherlands

Site Status

CLINICA RICARDO PALMA; Oftalmologos Contreras

Lima, , Peru

Site Status

Clinica Anglo Americana

Lima, , Peru

Site Status

OFTALMIKA Sp. z o.o

Bydgoszcz, , Poland

Site Status

Optimum Profesorskie Centrum Okulistyki

Gdansk, , Poland

Site Status

Gabinet Okulistyczny Prof Edward Wylegala

Katowice, , Poland

Site Status

SP ZOZ Szpital Uniwersytecki w Krakowie Oddział Kliniczny Okulistyki i Onkologii Okulistycznej

Krakow, , Poland

Site Status

Nemocnica sv. Michala, a.s.

Bratislava, , Slovakia

Site Status

Fakultna nemocnica Trencin Ocna klinika

Trenčín, , Slovakia

Site Status

Fakultna nemocnica s poliklinikou Zilina; Ocne oddelenie

Žilina, , Slovakia

Site Status

Hospital Universitari de Bellvitge; Servicio de Oftalmologia

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital General de Catalunya

San Cugat Del Valles, Barcelona, Spain

Site Status

Instituto Clinico Quirurgico de Oftalmologia - ICQO

Bilbao, Guipuzcoa, Spain

Site Status

VISSUM Instituto Oftalmológico de Alicante

Alicante, , Spain

Site Status

Institut de la Macula i la retina

Barcelona, , Spain

Site Status

FISABIO. Fundación Oftalmologica del Mediterraneo

Valencia, , Spain

Site Status

Hospital Universitario Rio Hortega; Servicio de Oftalmologia

Valladolid, , Spain

Site Status

Stadtspital Triemli; Augenklinik

Zurich, , Switzerland

Site Status

Ayr Hospital

Ayr, , United Kingdom

Site Status

The Princess Alexandra Eye Pavilion

Edinburgh, , United Kingdom

Site Status

Frimley Park Hospital

Frimley, , United Kingdom

Site Status

Royal Hallamshire Hospita

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Canada Denmark France Germany Hungary Italy Mexico Netherlands Peru Poland Slovakia Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Salvi A, Cluceru J, Gao SS, Rabe C, Schiffman C, Yang Q, Lee AY, Keane PA, Sadda SR, Holz FG, Ferrara D, Anegondi N. Deep Learning to Predict the Future Growth of Geographic Atrophy from Fundus Autofluorescence. Ophthalmol Sci. 2024 Oct 23;5(2):100635. doi: 10.1016/j.xops.2024.100635. eCollection 2025 Mar-Apr.

Reference Type DERIVED
PMID: 39758130 (View on PubMed)

Cluceru J, Anegondi N, Gao SS, Lee AY, Lad EM, Chakravarthy U, Yang Q, Steffen V, Friesenhahn M, Rabe C, Ferrara D. Topographic Clinical Insights From Deep Learning-Based Geographic Atrophy Progression Prediction. Transl Vis Sci Technol. 2024 Aug 1;13(8):6. doi: 10.1167/tvst.13.8.6.

Reference Type DERIVED
PMID: 39102242 (View on PubMed)

Bressler NM, Freund KB, Bakri SJ, Kim JE, Ferrara D, Brittain C, Pickthorn K, Lin H, Sun C, Martin J. Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy. JAMA Ophthalmol. 2024 Aug 1;142(8):772-776. doi: 10.1001/jamaophthalmol.2024.2061.

Reference Type DERIVED
PMID: 38900484 (View on PubMed)

Chang DS, Callaway NF, Steffen V, Csaky K, Guymer RH, Birch DG, Patel PJ, Ip M, Gao SS, Briggs J, Honigberg L, Lai P, Ferrara D, Sepah YJ. Macular Sensitivity Endpoints in Geographic Atrophy: Exploratory Analysis of Chroma and Spectri Clinical Trials. Ophthalmol Sci. 2023 Jun 12;4(1):100351. doi: 10.1016/j.xops.2023.100351. eCollection 2024 Jan-Feb.

Reference Type DERIVED
PMID: 37869030 (View on PubMed)

Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3.

Reference Type DERIVED
PMID: 37314061 (View on PubMed)

Miere A, Capuano V, Kessler A, Zambrowski O, Jung C, Colantuono D, Pallone C, Semoun O, Petit E, Souied E. Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. Comput Biol Med. 2021 Mar;130:104198. doi: 10.1016/j.compbiomed.2020.104198. Epub 2020 Dec 28.

Reference Type DERIVED
PMID: 33383315 (View on PubMed)

Heier JS, Pieramici D, Chakravarthy U, Patel SS, Gupta S, Lotery A, Lad EM, Silverman D, Henry EC, Anderesi M, Tschosik EA, Gray S, Ferrara D, Guymer R; Chroma and Spectri Study Investigators. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials. Ophthalmol Retina. 2020 Jul;4(7):673-688. doi: 10.1016/j.oret.2020.01.019. Epub 2020 Jan 31.

Reference Type DERIVED
PMID: 32199866 (View on PubMed)

Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, Brittain C, Ferrara D, Gray S, Honigberg L, Martin J, Tong B, Ehrlich JS, Bressler NM; Chroma and Spectri Study Investigators. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 2018 Jun 1;136(6):666-677. doi: 10.1001/jamaophthalmol.2018.1544.

Reference Type DERIVED
PMID: 29801123 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-000107-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GX29176

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736 COMPLETED PHASE2/PHASE3